Bradford Gessner
Overview
Explore the profile of Bradford Gessner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
137
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Williams S, Gessner B, Begier E, Aliabadi N, Ilangovan K, Jodar L, et al.
Infect Dis Ther
. 2024 Dec;
14(1):1-11.
PMID: 39680297
Lower respiratory tract illness or disease (LRTI/LRTD) represents a significant source of morbidity and mortality following viral respiratory illnesses, yet a consensus definition for this outcome is lacking. Recent studies...
2.
Hanquet G, Theilacker C, Vietri J, Sepulveda-Pachon I, Menon S, Gessner B, et al.
Infect Dis Ther
. 2024 Mar;
13(4):921-940.
PMID: 38498108
Introduction: Estimating the burden of lower respiratory tract infections (LRTIs) increasingly relies on administrative databases using International Classification of Diseases (ICD) codes, but no standard methodology exists. We defined best...
3.
Sundaramurthy S, Allen K, Fletcher M, Liew K, Borhanuddin B, Ali M, et al.
BMC Infect Dis
. 2024 Jan;
24(1):79.
PMID: 38216882
Background: Pneumococcal disease caused by Streptococcus pneumoniae is an important cause of morbidity and mortality across all ages, particularly in younger children and older adults. Here, we describe pneumococcal disease...
4.
Tippett A, Ess G, Hussaini L, Reese O, Salazar L, Kelly M, et al.
Clin Infect Dis
. 2023 Nov;
78(4):1065-1072.
PMID: 37946601
Background: Data are limited on influenza vaccine effectiveness (VE) in the prevention of influenza-related hospitalizations in older adults and those with underlying high-risk comorbidities. Methods: We conducted a prospective, test-negative,...
5.
Onwuchekwa C, Atwell J, Mora Moreo L, Menon S, Machado B, Siapka M, et al.
J Infect Dis
. 2023 Jun;
228(11):1516-1527.
PMID: 37285396
Background: Adding additional specimen types (eg, serology or sputum) to nasopharyngeal swab (NPS) reverse transcription polymerase chain reaction (RT-PCR) increases respiratory syncytial virus (RSV) detection among adults. We assessed if...
6.
Li Y, Kulkarni D, Begier E, Wahi-Singh P, Wahi-Singh B, Gessner B, et al.
Infect Dis Ther
. 2023 Mar;
12(4):1137-1149.
PMID: 36941483
Introduction: Previous studies suggest diagnostic testing characteristics (i.e. variations in clinical specimens and diagnostic tests) can contribute to underestimation of RSV disease burden. We aimed to improve the understanding of...
7.
Orsi A, Domnich A, Mosca S, Ogliastro M, Sticchi L, Prato R, et al.
Microorganisms
. 2023 Jan;
11(1).
PMID: 36677362
Pneumococcal community-acquired pneumonia (CAP) is a leading cause of mortality. Following the introduction of pneumococcal conjugate vaccines (PCVs) in children, a decrease in the burden of the disease was reported....
8.
Hyams C, Challen R, Marlow R, Nguyen J, Begier E, Southern J, et al.
Lancet Reg Health Eur
. 2022 Dec;
25:100556.
PMID: 36530491
Background: There is an urgent public health need to evaluate disease severity in adults hospitalised with Delta and Omicron SARS-CoV-2 variant infections. However, limited data exist assessing severity of disease...
9.
Skufca J, De Smedt N, Pilz A, Vyse A, Begier E, Blum M, et al.
Ticks Tick Borne Dis
. 2022 Sep;
13(6):102039.
PMID: 36166915
Lyme neuroborreliosis (LNB) can be a serious manifestation of Lyme borreliosis. We describe the incidence, time trends and geographic distribution of LNB in Denmark. We obtained LNB cases reported by...
10.
Njuma Libwea J, Fletcher M, Ndombo P, Boula A, Ashukem N, Ngo Baleba M, et al.
PLoS One
. 2021 Apr;
16(4):e0250010.
PMID: 33857235
Background: The 13-valent pneumococcal conjugate vaccine (PCV13) entered Cameroon's childhood national immunization programme (NIP) in July 2011 under a 3-dose schedule (6, 10, 14 weeks of age) without any catch-up....